COVID-19
Moderna, Pfizer and BioNTech and Johnson & Johnson earned an approximate combined revenue of $31 billion in 2021, thanks to the success of their mRNA vaccines against COVID-19.
The new normal may not be particularly new. Although cases appear to be dropping — deaths in the unvaccinated are still high. For that and more COVID-19 stories, continue reading.
Researchers identified a 19-nucleotide- long RNA sequence found in the SARS-CoV-2’s furin cleavage site that matched a 19-nucleotide sequence in a genetic segment owned by Moderna.
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.
Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.
The COVID-19 pandemic and the virus that causes it, SARS-CoV-2, has been resilient, unpredictable and confounding from the very beginning.
The U.S. Centers for Disease Control and Prevention is under fire for failing to publish large swaths of hospitalization data related to the COVID-19 pandemic.
It was noted early in the COVID-19 pandemic that the disease was peculiar — not only was it a respiratory disease, but it created hyper-immune responses.
PRESS RELEASES